Generating a generation of proteasome inhibitors: From microbial fermentation to total synthesis of salinosporamide A (marizomib) and other salinosporamides

Marine Drugs

Volumn 8, Issue 4, 2010, Pages 835-880

  Potts, Barbara C ^a   Lam, Kin S ^a,b  

^a Nereus Pharmaceuticals Inc   (United States)

^b Marrone Bio Innovations   (United States)

Author keywords

Analogs; Fermentation; Marizomib; Mutasynthesis; Natural products chemistry; NPI 0052; Precursor directed biosynthesis; Proteasome inhibitor; Salinosporamide A; Semi synthesis; Structure activity relationships; Total synthesis

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIPROTEALIDE; AZIDOSALINOSPORAMIDE; BORTEZOMIB; BROMOSALINOSPORAMIDE; HYDROXYSALINOSPORAMIDE; IODOSALINOSPORAMIDE; KETOSALINOSPORAMIDE; MESYLSALINOSPORAMIDE; NATURAL PRODUCT; NPI 0047; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SALINOSPORAMIDE B; SALINOSPORAMIDE C; SALINOSPORAMIDE D; SALINOSPORAMIDE DERIVATIVE; SALINOSPORAMIDE E; SALINOSPORAMIDE F; SALINOSPORAMIDE G; SALINOSPORAMIDE H; SALINOSPORAMIDE J; SALINOSPORAMIDE X2; SALINOSPORAMIDE X3; SALINOSPORAMIDE X5; SALINOSPORAMIDE X6; SALINOSPORAMIDE X7; THIOCYANOSALINOSPORAMIDE; TOSYLSALINOSPORAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTINOMYCES; BACTERIAL STRAIN; CLINICAL TRIAL; DERIVATIZATION; DRUG CYTOTOXICITY; DRUG ISOLATION; DRUG MECHANISM; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOSELECTIVITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; FERMENTATION TECHNIQUE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHUMAN; RACEMIZATION; REVIEW; SALINISPORA TROPICA; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 77952555794     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md8040835     Document Type: Review

References (111)

1. Ciechanover, A. Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ. 2005, 12, 1178-1190.
2. Hershko, A.; Ciechanover, A., The ubiquitin system. Ann. Rev. Biochem. 1998, 67, 425-479.
3. Borissenko, L.; Groll, M. 20S Proteasome and its inhibitors: Crystallographic knowledge for drug development. Chem. Rev. 2007, 107, 687-717. (Pubitemid 46502369)
4. Adams, J. Proteasome Inhibitors in Cancer Therapy; Humana Press: Totowa, NJ, USA, 2004.
5. Orlowski, R.Z.; Kuhn, D.J. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin. Cancer Res. 2008, 14, 1649-1657. (Pubitemid 351469448)
6. Moore, B.S.; Eustǎquio, A.S.; McGlinchey, R.P. Advances in and applications of proteasome inhibitors. Curr. Opin. Chem. Biol. 2008, 12, 434-440.
7. Hillebrand, S.; Guth, O.; Wiese, W.-B.; Kunz, K.; Ullmann, A.; Mattes, A.; Schreier, P.; Wachendorff-Neumann, U.; Kuck, K.-H.; Lösel, P.; Malsam, O.; Reinemer, P.; Stadler, M.; Seip, S.; Mayer-Bartschmid, A.; Müller, H.; Bacon, K. Substituted 2-pyrrolidone derivatives as fungicides and insecticides. Int. Publ. 2006, WO 2006/005551 A1.
8. Prudhomme, J.; McDaniel, E.; Ponts, N.; Bertani, S.; Fenical, W.; Jensen, P.; Le Roch, K. Marine actinomycetes: A new source of compounds against the human malaria parasite. PLoS One 2008, 3, e2335.
9. Skaug, B.; Jiang, X.; Chen, Z.J., The role of ubiquitin in NF-kappaB regulatory pathways. Ann. Rev. Biochem. 2009, 78, 769-796.
10. Richarson, P.G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S.V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348, 2609-2617.
11. Bross, P.F.; Kane, R.; Farrell, A.T.; Abraham, S.; Benson, K.; Brower, M.E.; Bradley, S.; Gobburu, J.V.; Goheer, A.; Lee, S.-L.; et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res. 2004, 10, 3954-3964.
12. Chauhan, D.; Hideshima, T.; Anderson, K.C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Brit. J. Cancer 2006, 95, 961-965. (Pubitemid 44606819)
13. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N; Yasui, H.; Letai, A.; et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005, 8, 407-419.
14. Stapnes, C.; Gjertsen, B.T.; Reikvam, H.; Bruserud, O. Targeted therapy in acute myeloid leukaemia: Current status and future directions. Expert Opin. Investig. Drugs 2009, 18, 433-455.
15. Feling, R.H.; Buchanan, G.O.; Mincer, T.J.; Kauffman, C.A.; Jensen, P.R.; Fenical, W. Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew. Chem. Int. Ed. 2003, 42, 355-357.
16. Fenical, W.H.; Jensen, P.R.; Palladino, M.A.; Lam, K.S.; Lloyd, G.K.; Potts, B.C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem. 2009, 17, 2175-2180.
17. Lam, K.S.; Lloyd, G.K.; Neuteboom, S.T.C.; Palladino, M.A.; Sethna, K.M. Spear, M.A.; Potts, B.C. From natural product to clinical trials: NPI-0052 (salinosporamide A), a marine actinomycete-derived anticancer agent. In Natural Products Chemistry for Drug Discovery; Buss, A.D., Butler, M.S., Eds.; Royal Society of Chemistry: Cambridge, UK, 2010; RSC Biomolecular Sciences No. 18, pp. 355-373.
18. Chauhan, D.; Singh, A.; Brahmandam, M.; Podar, K.; Hideshima, T.; Richardson, P.; Munshi, N.; Palladino, M.A.; Anderson, K.C. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008, 111, 1654-1664.
19. Ruiz, S.; Krupnik, Y.; Keating, M.; Chandra, J.; Palladino, M.; McConkey, D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol. Cancer Ther. 2006, 5, 1836-1843. (Pubitemid 44323252)
20. Miller, C.P.; Ban, K.; Dujka, M.E.; McConkey, D.J.; Munsell, M.; Palladino, M.; Chandra, J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007, 110, 267-277. (Pubitemid 47026844)
21. Miller, C.P.; Rudra, S.; Keating, M.J.; Wierda, W.G.; Palladino, M.; Chandra, J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: A mechanism for synergy in leukemia cells. Blood 2009, 113, 4289-4299.
22. Cusack, J.C., Jr.; Liu, R.; Xia, L.; Chao, T.H.; Pien, C.; Niu, W.; Palombella, V.J.; Neuteboom, S.T.; Palladino, M.A. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin. Cancer Res. 2006, 12, 6758-6764.
23. Omura, S.; Fujimoto, T.; Otoguro, K.; Matsuzaki, K.; Moriguchi, R.; Tanaka, H.; Sasaki, Y. Lactacystin, a novel microbial metabolite induces neuritogenesis of neuroblastoma cells. J. Antibiot. 1991, 44, 113-116.
24. Omura, S.; Matsuzaki, K.; Fujimoto, T.; Kosuge, K.; Furuya, T.; Fujita, S.; Nakagawa, A. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J. Antibiot. 1991, 44, 117-118.
25. Fenteany, G.; Standaert, R.F.; Lane, W.S.; Choi, S.; Corey, E.J.; Schreiber, S.L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995, 268, 726-731.
26. Dick, L.R.; Cruikshank, A.A.; Grenier, L.; Melandri, F.D.; Nunes, S.L.; Stein, R.L. Mechanistic studies on the inactivation of the proteasome by lactacystin. J. Biol. Chem. 1996, 271, 7273-7276.
27. Dick, L.R.; Cruikshank, A.A.; Destree, A.T.; Grenier, L.; McCormack, T.A.; Melandri, F.D.; Nunes, S.L.; Palombello, V.J.; Parent, L.A.; Plamondon, L.; Stein, R.L. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J. Biol. Chem. 1997, 272, 182-188.
28. Groll, M.; Ditzel L.; Löwe J.; Stock D.; Bochtler, M.; Bartunik, H.D.; Huber, R. Structure of 20S proteasome from yeast at 2.4Å resolution. Nature 1997, 386, 463-471. (Pubitemid 27164066)
29. Corey, E.J.; Li, W.Z. Total synthesis and biological activity of lactacystin, omuralide, and analogs. Chem. Pharm. Bull. 1999, 47, 1-10.
30. Masse, C.E.; Morgan, A.J.; Adams, J.; Panek, J.S. Syntheses and biological evaluation of (+)-lactacystin and analogs. Eur. J. Org. Chem. 2000, 2513-2528.
31. Kang, S.H.; Kang, S.Y.; Lee, H.-S.; Buglass, A.J. Total synthesis of natural tert-alkylamino hydroxy carboxylic acids. Chem. Rev. 2005, 105, 4537-4558. (Pubitemid 43091996)
32. Shibasaki, M.; Kanai, M.; Fukuda, N. Total synthesis of lactacystin and salinosporamide A. Chem. Asian J. 2007, 2, 20-38.
33. Shah, I.M.; Lees, K.R.; Pien, C.P.; Elliot, P.J. Early clinical experience with the novel proteasome inhibitor PS-519. Br. J. Clin. Pharmacol. 2002, 54, 269-276.
34. Macherla, V.R.; Mitchell, S.S.; Manam, R.R.; Reed, K.; Chao, T.-H.; Nicholson, B.; Deyanat-Yazdi, G.; Mai, B.; Jensen, P.R.; Fenical, W.; et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J. Med. Chem. 2005, 48, 3684-3687.
35. Groll, M.; Huber, R.; Potts, B.C.M. Crystal structure of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc. 2006, 128, 5136-5141.
36. Millward, M.; Spear, M.A.; Townsend, A.; Sweeney, C.; Sukumaran, S.; Longenecker, A.; Palladino, M.A.; Lloyd, G.K.; Neuteboom, S.T.C.; Price, T. Clinical trial combining proteasome (NPI-0052) and HDAC (vorinostat) inhibition in melanoma, pancreatic and lung cancer. Mol. Cancer Ther. 2009, 8, Abstr. 107; Meeting Abstract Supplement.
37. Townsend, A.R.; Millward, M.; Price, T.; Mainwaring, P.; Spencer, A.; Longenecker, A.; Palladino, M.A.; Lloyd, G.K.; Spear, M.A.; Padrik, P. Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (Advanced Malignancies Arm). J. Clin. Oncol. 2009, 27, 15s.
38. Hamlin P.A.; Aghajanian, C.; Younes, A.; Hong, D.S.; Palladino, M.A.; Longenecker, A.M.; Lloyd, G.K.; Hannah, A.L.; Spear, M.A.; Kurzrock, R. First-in-human phase 1 study of the novel structure proteasome inhibitor NPI-0052. J. Clin. Oncol. 2009, 27, 15s.
39. Reddy, L.R.; Saravanan, P.; Corey, E.J. A simple stereocontrolled synthesis of salinosporamide A. J. Am. Chem. Soc. 2004, 126, 6230-6231.
40. Endo, A.; Danishefsky, S.J. Total synthesis of salinosporamide A. J. Am. Chem. Soc. 2005, 127, 8298-8299.
41. Ling, T.; Macherla, V.R.; Manam, R.R.; McArthur, K.A.; Potts, B.C.M. Enantioselective total synthesis of (-)-salinosporamide A (NPI-0052). Org. Lett. 2007, 9, 2289-2292.
42. Takahashi, K.; Midori, M.; Kawano, K.; Ishihara, J.; Hatakeyama, S. Entry to heterocycles based on indium-catalyzed Conia-ene reactions: Asymmetric synthesis of (-)-salinosporamide A. Ang. Chem. Int. Ed. 2008, 47, 6244-6246.
43. Fukuda, T.; Sugiyama, K.; Arima, S.; Harigaya, Y.; Nagamitsu, T.; Omura, S. Total synthesis of salinosporamide A. Org. Lett. 2008, 10, 4239-4242.
44. Mulholland, N.P.; Pattenden, G.; Walters, I.A.S. A concise total synthesis of salinosporamide A. Org. Biomol. Chem. 2006, 4, 2845-2846.
45. Ma, G.; Nguyen, H.; and Romo, D. Concise total synthesis of (±)-salinosporamide A, (±)-cinnabaramide A, and derivatives via a bis-cyclization process; implications for a biosynthetic pathway? Org. Lett. 2007, 9, 2143-2146.
46. Caubert, V.; Masse, J.; Retailleau, P.; Langlois, N. Stereoselective formal synthesis of the potent proteasome inhibitor: Salinosporamide A. Tetrahedron Lett. 2007, 48, 381-384. (Pubitemid 44894512)
47. Margalef, I.V.; Rupnicki, L.; Lam, H.W. Formal synthesis of salinosporamide A using a nickel-catalyzed reductive aldol cyclization- lactonization as a key step. Tetrahedron 2008, 64, 7896-7901.
48. Struble, J.R.; Bode, J.W. Formal synthesis of salinosporamide A via NHC-catalyzed intramolecular lactonization. Tetrahedron 2009, 65, 4957-4967.
49. Mosey, R.A.; Tepe, J.J. New synthetic route to access (±) salinosporamide A via an oxazolone-mediated ene-type reaction. Tetrahedron Lett. 2009, 50, 295-297.
50. Momose, T.; Kaiya, Y.; Hasegawa, J.; Sato, T.; Chida, N. Formal synthesis of salinosporamide A starting from D-glucose. Synthesis 2009, 17, 2983-2991.
51. Williams, P.G.; Buchanan, G.O.; Feling, R.H.; Kauffman, C.A.; Jensen, P.R., Fenical, W. New cytotoxic salinosporamides from the marine actinomycete Salinispora tropica. J. Org. Chem. 2005, 70, 6196-6203. (Pubitemid 41076500)
52. Reed, K.A.; Manam, R.R.; Mitchell, S.S.; Xu, J; Teisan, S.; Chao, T-H.; Deyanat-Yazdi, G.; Neuteboom, S.T.C.; Lam, K.S.; Potts, B.C.M. Salinosporamides D-J from the marine actinomycete Salinospora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasome. J. Nat. Prod. 2007, 70, 269-276.
53. Manam, R.R.; Macherla, V.R.; Tsueng, G.; Dring, C.W.; Weiss, J.; Neuteboom, S.T.; Lam, K.S.; Potts, B.C. Antiprotealide is a natural product. J. Nat. Prod. 2009, 72, 295-297.
54. Lam, K.S.; Tsueng, G.; McArthur, K.A.; Mitchell, S.S.; Potts, B.C.M.; Xu, J. Effects of halogens on the production of salinosporamides by the obligate marine actinomycete Salinispora tropica. J. Antibiot. 2007, 60, 13-19.
55. Tsueng, G.; McArthur, K.A.; Potts, B.C.M.; Lam, K.S. Unique butyric acid incorporation patterns for salinosporamides A and B reveal distinct biosynthetic origins. Appl. Microbiol. Biotechnol. 2007, 75, 999-1005.
56. Beer, L.L.; Moore, B.S. Biosynthetic convergence of salinosporamides A and B in the marine actinomycete Salinospora tropica. Org. Lett. 2007, 9, 845-848.
57. Tsueng, G.; Teisan, S.; Lam, K.S. Defined salt formulations for the growth of Salinispora tropica strain NPS21184 and the production of salinosporamide A (NPI-0052) and related analogs. Appl. Microbiol. Biotechnol. 2008, 78, 827-832.
58. 12 on the production of salinosporamides by Salinispora tropica. J. Antibiot. 2009, 62, 213-216.
59. Potts, B.C.; Macherla, V.R.; Mitchell, S.S.; Manam, R.R.; Reed, K.A.; Lam, K.S.; Neuteboom, S.T.C.; Chao, T-H.; Nicholson, B.; Billstrom, C. [3.2.0]Heterocyclic compounds and methods of using the same. WO 2006/028525 A2, March 16, 2006.
60. Manam, R.R.; Macherla, V.R.; Potts, B.C.M. Stereoselective enzymatic reduction of ketosalinosporamide to (-)-salinosporamide A (NPI-0052). Tetrahedron Lett. 2007, 48, 2537-2540.
61. Manam, R.R.; McArthur, K.A.; Chao, T-H.; Weiss, J.; Ali, J.A.; Palombella, V.J.; Groll, M.; Lloyd, G.K.; Palladino, M.A.; Neuteboom, S.T.C.; et al. Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides. J. Med. Chem. 2008, 51, 6711-6724.
62. Udwary, D.W.; Zeigler, L.; Asolkar, R.N.; Singan, V.; Lapidus, A.; Fenical, W.; Jensen, P.R.; Moore, B.S. Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinospora tropica. Proc. Natl. Acad. Sci. USA 2007, 104, 10376-10381.
63. Eustǎquio, A.S.; Moore, B.S. Mutasynthesis of fluorosalinosporamide, a potent and reversible inhibitor of the proteasome. Angew. Chem. Int. Ed. 2008, 47, 3936-3938.
64. McGlinchey, R.P.; Nett, M.; Eustǎquito, A.S.; Asolkar, R.N.; Fenical W.; Moore, B.S. Engineered biosynthesis of antiprotealide and other unnatural salinosporamide proteasome inhibitors. J. Am. Chem. Soc. 2008, 130, 7822-7823. (Pubitemid 351875047)
65. Nett, M.; Gulder, T.A.M.; Kale, A.J.; Hughes, C.C.; Moore B.S. Function-oriented biosynthesis of β-lactone proteasome inhibitors in Salinispora tropica. J. Med. Chem. 2009, 52, 6163-6167.
66. Eustǎquio, A.S.; O'Hagen, D.; Moore, B.S. Engineering fluorometabolite production: Fluorinase expression in Salinispora tropica yields fluorosalinosporamide. J. Nat. Prod. 2010, doi:10.1021/np900719u.
67. Groll, M.; McArthur, K.A.; Macherla, V.R.; Manam, R.R.; Potts, B.C. Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition. J. Med. Chem. 2009, 52, 5420-5428.
68. Eustǎquio, A.S.; Pojer, F.; Noel, J.P.; Moore, B.S. Discovery and characterization of a marine bacterial SAM-dependent chlorinase. Nat. Chem. Biol. 2008, 4, 69-74. (Pubitemid 350273655)
69. Mincer, T.J.; Jensen, P.R.; Kauffman, C.A.; Fenical, W. Widespread and persistent populations of a major new marine actinomycete taxon in ocean sediments. Appl. Environ. Microbiol. 2002, 68, 5005-5011.
70. Maldonado, L.; Fenical, W.; Jensen, P.R.; Kauffman, C.K.; Mincer, T.J.; Ward, A.C.; Bull, A.T.; Goodfellow, M. Salinispora arenicola gen. nov., sp. nov. and Salinispora tropica sp. nov., obligate marine actinomycetes belonging to the family Micromonosporaceae. Int. J. Syst. Evol. Microbiol. 2005, 55, 1759-1766.
71. Reddy, L.R.; Fournier, J.F.; Reddy, B.V.S.; Corey, E.J. An efficient, stereocontrolled synthesis of a potent omuralide-salinosporin hybrid for selective proteasome inhibition. J. Am. Chem. Soc. 2005, 127, 8974-8976.
72. Reddy, L.R.; Fournier, J.-F.; Reddy, B.V.S.; Corey, E.J. New synthetic route for the enantioselective total synthesis of salinosporamide A and biologically active analogues. Org. Lett., 2005, 7, 2699-2701.
73. Lee, W.W.; Benitez, A.; Goodman, L.; Baker, B.R. Potential anticancer agents. XL. Synthesis of the β-anomer of 9-(D-arabinofuranosyl)-adenine. J. Am. Chem. Soc. 1960, 82, 2648-2649.
74. Howells, J.D.; Ryder, A. (Parke, Davis and Co.) Fermentation process for 9-(β-D-arabinofuranosyl) adenine. US Patent 3,616,208, 26 October, 1971.
75. Stadler, M.; Bitzer, J.; Mayer-Bartschmid, A.; Müller, H.; Benet-Buchholz, J.; Gantner, F.; Tichy, H.V.; Reinemer, P.; Bacon, K.B. Cinnabaramides A-G: Analogues of lactacystin and salinosporamide from a terrestrial streptomycete. J. Nat. Prod. 2007, 70, 246-252.
76. 1 by Actinomadura verrucosospora. J. Ind. Microbiol. 1993, 12, 99-102.
77. Lam, K.S.; Veitch, J.A.; Lowe, S.E.; Forenza, S. Effect of neutral resins on the production of dynemicins by Micromonospora cherisina. J. Ind. Microbiol. 1995, 15, 453-456. (Pubitemid 26026986)
78. Woo, E.J.; Starks, C.M.; Carney, J.R.; Arslanian, R.; Cadapan, L.; Zavala, S.; Licari, P. Migrastatin and a new compound, isomigrastatin, from Streptomyces platensis. J. Antibiot. 2002, 55, 141-146.
79. Frykman, S.; Tsuruta, H.; Galazzo, J.; Licari, P. Characterization of product capture resin during microbial cultivations. J. Ind. Microbiol. Biotechnol. 2006, 33, 445-453.
80. Denora, N.; Potts, B.C.M.; Stella, V.J. A mechanistic and kinetic study of the β-lactone hydrolysis of salinosporamide A (NPI-0052), a novel proteasome inhibitor. J. Pharm. Sci. 2007, 96, 2037-2047.
81. Tsueng, G.; Lam, K.S. Stabilization effect of resin on the production of potent proteasome inhibitor NPI-0052 during submerged fermentation of Salinispora tropica. J. Antibiot. 2007, 60, 469-472.
82. Sedriks, J.A. Corrosions of Stainless Steels, 2nd ed.; Wiley: New York, NY, USA, 1996.
83. Thiericke, R.; Rohn, J. Biological variation of microbial metabolites by precursor-directed biosynthesis. Nat. Prod. Rep. 1993, 10, 265-289.
84. Ritacco, F.V.; Graziani, E.I.; Summers, M.Y.; Zabriskie, T.M.; Yu, K.; Bernan, V.S.; Carter, G.T.; Greenstein, M. Production of novel rapamycin analogs by precursor-directed biosynthesis. Appl. Environ. Microbiol. 2005, 71, 1971-1976. (Pubitemid 40546120)
85. Moran, S.; Rai, D.K.; Clark, B.R.; Murphy, C.D. Precursor-directed biosynthesis of fluorinated iturin A in Bacillus spp. Org. Biomol. Chem. 2009, 7, 644-646.
86. Güschow, S.; Rackham, E.J.; Elkins, B.; Newill, P.L.; Hill, L.M.; Gross, R.J. New apacidamycin antibiotics through precursor-directed biosynthesis. ChemBioChem 2009, 10, 355-360.
87. Amir-Heidari, B.; Thirlway, J.; Micklefield J. Auxotrophic-precursor directed biosynthesis of nonribosomal lipopeptides with modified tryptophan residues. Org. Biomol. Chem. 2008, 6, 975-978.
88. Stirrett, K.; Denoya, C.; Westpheling, J. Branched-chain amino acid catabolism provides precursors for the type II polyketide antibiotic, actinorhodin, via pathways that are nutrient dependent. J. Ind. Microbiol. Biotechnol. 2009, 36, 129-137.
89. Nagaoka K.; Demain A.L. Mutational biosynthesis of a new antibiotic, streptomutin A, by an idiotroph of Streptomyces griseus. J. Antibiot. 1975, 28, 627-635.
90. Rinehart, K.L., Jr.; Stroshane, R.M. Biosynthesis of aminocyclitol antibiotics. J. Antibiot. 1976, 29, 319-353.
91. Levengood, M.R.; Knerr, P.J.; Oman, T.J.; van der Donk, W.A. In vitro mutasynthesis of lantibiotic analogues containing nonproteinogenic amino acids. J. Am. Chem. Soc. 2009, 131, 12024-12025.
92. Eichner, S.; Floss, H.G.; Sasse, F.; Kirschning A. New, highly active nonbenzoquinone geldanamycin derivatives by using mutasynthesis. ChemBioChem 2009, 10, 1801-1805.
93. Heide, L. Genetic engineering of antibiotic biosynthesis for the generation of new aminocoumarins. Biotechnol. Adv. 2009, 27, 1006-1014.
94. Gupta, S.; Lakshmanan, V.; Kim, B.S.; Fecik, R.; Reynolds, K.A. Generation of novel pikromycin antibiotic products through mutasynthesis. ChemBioChem 2008, 9, 1609-1616.
95. Donadio, S.; Sosio, M. Biosynthesis of glycopeptides: Prospects for improved antibacterials. Curr. Top. Med. Chem. 2008, 8, 654-666. (Pubitemid 351982573)
96. Tannhauser, P.; Pratt, R.J.; Jensen, E.V. The preparation of 21-flurosteroids. J. Am. Chem. Soc. 1956, 78, 2658-2659.
97. Ando, T.; Cork, D.G.; Fujita, M.; Kimura, T.; Tatsuno, T. Silver fluoride supported on calicium fluoride. Improved fluorination and halofluorination reactions. Chem. Lett. 1988, 1877-1878.
98. Fenteany, G.; Schreiber, S.L. Lactacystin, proteasome function, and cell fate. J. Biol. Chem. 1998, 273, 8545-8548.
99. Seebach, D.; Sting, A.R.; Hoffman, M. Self-regeneration of stereocenters (SRS)-applications, limitations, and abandonment of a synthetic principle. Angew. Chem. Int. Ed. 1996, 35, 2708-2748.
100. Andrews, M.D.; Brewster, A.G.; Moloney, M.G. Highly functionalized pyroglutamates by intramolecular aldol reactions: Towards the pyroglutamate skeleton of oxazolomycin. Synlett 1996, 612-614.
101. Kramer, G.W.; Brown, H.C. Organoboranes: XIX. The preparation and some unusual chemistry of b-allyl derivatives of 9-borabicyclo[3.3.1]nonane. J. Organomet. Chem. 1977, 132, 9-27.
102. Conia, J.M.; Le Perchec, P. The thermal cyclisation of unsaturated carbonyl compounds. Synthesis 1975, 1, 1-19.
103. Hatakeyama, S. Indium-catalyzed Conia-ene reaction for alkaloid synthesis. Pure Appl. Chem. 2009, 81, 217-226.
104. Mulholland, N.P.; Pattenden, G.; Walters, I.A.S. A concise and straightforward total synthesis of (±)-salinosporamide A, based on a biosynthetic model. Org. Biomol. Chem. 2008, 6, 2782-2789.
105. Henry-Riyad, H.; Lee, C.S.; Purohit, V.C.; Romo, D. Bicyclic- and tricyclic-beta-lactones via organonucleophile-promoted bis-cyclizations of keto acids: Enantioselective synthesis of (+)-dihydroplakevulin. Org. Lett. 2006, 8, 4363-4366.
106. Caubert, V.; Langlois, N. Studies toward the synthesis of salinosporamide A, a potent proteasome inhibitor. Tetrahedron Lett. 2006, 47, 4473-4475. (Pubitemid 43767591)
107. Langlois, N.; Le Nguyen, B.K. Diastereoselective syntheses of deoxydysibetaine, dysibetaine and its 4-epimer. J. Org. Chem. 2004, 69, 7558-7564.
108. Joensuu, P.M.; Murray, G.J.; Fordyce, E.A.F.; Luebbers, T.; Lam, H.W. Selective nickel-catalyzed reductive aldol cyclizations using diethylzinc as the stoichiometric reductant: Scope and mechanistic insight. J. Am. Chem. Soc. 2008, 130, 7328-7338.
109. Hewlett, N.M.; Hupp, C.D.; Tepe, J.J. Reactivity of oxazol-5-(4H)-ones and their application toward natural product synthesis. Synthesis 2009, 17, 2825-2839.
110. Chida, N.; Takeoka, J.; Ando, K.; Tsutsumi, N.; Ogawa, S. Stereoselective total synthesis of (+)-lactacystin from D-glucose. Tetrahedron 1997, 53, 16287-16298.
111. Fleet, G.W.J.; James, K.; Lunn, R.J.; Matthews, C.J. An enantiospecific synthesis of S-quinuclidinol from D-glucose. Tetrahedron Lett. 1986, 27, 3057-3058.